Diet as a Trigger or Therapy for Inflammatory Bowel Diseases

Gastroenterology

Volumn 152, Issue 2, 2017, Pages 398-414.e6

  Lewis, James D ^a   Abreu, Maria T ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Diet; Inflammatory Bowel Disease; Microbiome; Short Chain Fatty Acids

Indexed keywords

CURCUMIN; EMULSIFYING AGENT; FOOD ADDITIVE; OMEGA 3 FATTY ACID; SHORT CHAIN FATTY ACID; VITAMIN D; FAT INTAKE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEGA 6 FATTY ACID; VOLATILE FATTY ACID;

ARTICLE; CARBOHYDRATE DIET; CROHN DISEASE; DIET THERAPY; DIETARY FIBER; DIETARY SUPPLEMENT; DRUG EFFICACY; DYSBIOSIS; ENTERIC FEEDING; HUMAN; INFLAMMATORY BOWEL DISEASE; INTESTINE FLORA; NONHUMAN; PRIORITY JOURNAL; RELAPSE; ULCERATIVE COLITIS; VITAMIN SUPPLEMENTATION; DIET; FAT INTAKE; FERMENTATION; FRUIT; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; RISK FACTOR; STATISTICS AND NUMERICAL DATA; VEGETABLE; VITAMIN D DEFICIENCY;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CROHN DISEASE; CURCUMIN; DIET; DIET THERAPY; DIETARY FATS; DIETARY FIBER; DIETARY SUPPLEMENTS; DYSBIOSIS; EMULSIFYING AGENTS; FATTY ACIDS, OMEGA-6; FATTY ACIDS, VOLATILE; FERMENTATION; FRUIT; GASTROINTESTINAL MICROBIOME; HUMANS; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; RISK FACTORS; VEGETABLES; VITAMIN D DEFICIENCY;

EID: 85007420709     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2016.10.019     Document Type: Article

References (226)

1. 1 Liu, J.Z., van Sommeren, S., Huang, H., et al. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat Genet 47 (2015), 979–986.
2. 2 Mahid, S.S., Minor, K.S., Soto, R.E., et al. Smoking and inflammatory bowel disease: a meta-analysis. Mayo Clin Proc 81 (2006), 1462–1471.
3. 3 Frank, D.N., St Amand, A.L., Feldman, R.A., et al. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A 104 (2007), 13780–13785.
4. 4 Wu, G.D., Chen, J., Hoffmann, C., et al. Linking long-term dietary patterns with gut microbial enterotypes. Science 334 (2011), 105–108.
5. 5 Claesson, M.J., Jeffery, I.B., Conde, S., et al. Gut microbiota composition correlates with diet and health in the elderly. Nature 488 (2012), 178–184.
6. 6 David, L.A., Maurice, C.F., Carmody, R.N., et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature 505 (2014), 559–563.
7. 7 Lewis, J.D., Chen, E.Z., Baldassano, R.N., et al. Inflammation, antibiotics, and diet as environmental stressors of the gut microbiome in pediatric Crohn's disease. Cell Host Microbe 18 (2015), 489–500.
8. 8 Zhernakova, A., Kurilshikov, A., Bonder, M.J., et al. Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity. Science 352 (2016), 565–569.
9. 9 Molodecky, N.A., Soon, I.S., Rabi, D.M., et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 142 (2012), 46–54.e42 quiz e30.
10. 10 Ananthakrishnan, A.N., Khalili, H., Konijeti, G.G., et al. A prospective study of long-term intake of dietary fiber and risk of Crohn's disease and ulcerative colitis. Gastroenterology 145 (2013), 970–977.
11. 11 Charlebois, A., Rosenfeld, G., Bressler, B., The impact of dietary interventions on the symptoms of inflammatory bowel disease: a systematic review. Crit Rev Food Sci Nutr 56 (2016), 1370–1378.
12. 12 Damas, O.M., Jahann, D.A., Reznik, R., et al. Phenotypic manifestations of inflammatory bowel disease differ between Hispanics and non-Hispanic whites: results of a large cohort study. Am J Gastroenterol 108 (2013), 231–239.
13. 13 Barclay, A.R., Russell, R.K., Wilson, M.L., et al. Systematic review: the role of breastfeeding in the development of pediatric inflammatory bowel disease. J Pediatr 155 (2009), 421–426.
14. 14 Bernstein, C.N., Banerjee, A., Targownik, L.E., et al. Cesarean section delivery is not a risk factor for development of inflammatory bowel disease: a population-based analysis. Clin Gastroenterol Hepatol 14 (2016), 50–57.
15. 15 Dotan, I., Alper, A., Rachmilewitz, D., et al. Maternal inflammatory bowel disease has short and long-term effects on the health of their offspring: a multicenter study in Israel. J Crohns Colitis 7 (2013), 542–550.
16. 16 Yatsunenko, T., Rey, F.E., Manary, M.J., et al. Human gut microbiome viewed across age and geography. Nature 486 (2012), 222–227.
17. 17 Lim, E.S., Zhou, Y., Zhao, G., et al. Early life dynamics of the human gut virome and bacterial microbiome in infants. Nat Med 21 (2015), 1228–1234.
18. 18 Jakobsson, H.E., Abrahamsson, T.R., Jenmalm, M.C., et al. Decreased gut microbiota diversity, delayed Bacteroidetes colonisation and reduced Th1 responses in infants delivered by caesarean section. Gut 63 (2014), 559–566.
19. 19 Backhed, F., Roswall, J., Peng, Y., et al. Dynamics and stabilization of the human gut microbiome during the first year of life. Cell Host Microbe, 17, 2015, 852.
20. 20 Planer, J.D., Peng, Y., Kau, A.L., et al. Development of the gut microbiota and mucosal IgA responses in twins and gnotobiotic mice. Nature 534 (2016), 263–266.
21. 21 Racine, A., Carbonnel, F., Chan, S.S., et al. Dietary patterns and risk of inflammatory bowel disease in Europe: results from the EPIC study. Inflamm Bowel Dis 22 (2016), 345–354.
22. 22 Tjonneland, A., Overvad, K., Bergmann, M.M., et al. Linoleic acid, a dietary n-6 polyunsaturated fatty acid, and the aetiology of ulcerative colitis: a nested case-control study within a European prospective cohort study. Gut 58 (2009), 1606–1611.
23. 23 Ananthakrishnan, A.N., Khalili, H., Konijeti, G.G., et al. Long-term intake of dietary fat and risk of ulcerative colitis and Crohn's disease. Gut 63 (2014), 776–784.
24. 24 Hart, A.R., Luben, R., Olsen, A., et al. Diet in the aetiology of ulcerative colitis: a European prospective cohort study. Digestion 77 (2008), 57–64.
25. 25 Pitcher, M.C., Cummings, J.H., Hydrogen sulphide: a bacterial toxin in ulcerative colitis?. Gut 39 (1996), 1–4.
26. 26 Wallace, J.L., Vong, L., McKnight, W., et al. Endogenous and exogenous hydrogen sulfide promotes resolution of colitis in rats. Gastroenterology 137 (2009), 569–578 578.e1.
27. 27 Coffey, J.C., Docherty, N.G., O'Connell, P.R., Hydrogen sulphide: an increasing need for scientific equipoise. Gastroenterology 137 (2009), 2181–2182 author reply 2182.
28. 28 Fiorucci, S., Orlandi, S., Mencarelli, A., et al. Enhanced activity of a hydrogen sulphide-releasing derivative of mesalamine (ATB-429) in a mouse model of colitis. Br J Pharmacol 150 (2007), 996–1002.
29. 29 Werner, T., Wagner, S.J., Martinez, I., et al. Depletion of luminal iron alters the gut microbiota and prevents Crohn's disease-like ileitis. Gut 60 (2011), 325–333.
30. 30 Weiss, G., Iron in the inflamed gut: another pro-inflammatory hit?. Gut 60 (2011), 287–288.
31. 31 Ananthakrishnan, A.N., Khalili, H., Song, M., et al. High school diet and risk of Crohn's disease and ulcerative colitis. Inflamm Bowel Dis 21 (2015), 2311–2319.
32. 32 Patel, B., Schutte, R., Sporns, P., et al. Potato glycoalkaloids adversely affect intestinal permeability and aggravate inflammatory bowel disease. Inflamm Bowel Dis 8 (2002), 340–346.
33. 33 Chng, S.H., Kundu, P., Dominguez-Brauer, C., et al. Ablating the aryl hydrocarbon receptor (AhR) in CD11c+ cells perturbs intestinal epithelium development and intestinal immunity. Sci Rep, 6, 2016, 23820.
34. 34 Zelante, T., Iannitti, R.G., Cunha, C., et al. Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. Immunity 39 (2013), 372–385.
35. 35 Jaeger, C., Tischkau, S.A., Role of aryl hydrocarbon receptor in circadian clock disruption and metabolic dysfunction. Environ Health Insights 10 (2016), 133–141.
36. 36 Lee, J.Y., Zhao, L., Hwang, D.H., Modulation of pattern recognition receptor-mediated inflammation and risk of chronic diseases by dietary fatty acids. Nutr Rev 68 (2010), 38–61.
37. 37 Hwang, D.H., Kim, J.A., Lee, J.Y., Mechanisms for the activation of Toll-like receptor 2/4 by saturated fatty acids and inhibition by docosahexaenoic acid. Eur J Pharmacol 785 (2016), 24–35.
38. 38 Round, J.L., Mazmanian, S.K., The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol 9 (2009), 313–323.
39. 39 Elinav, E., Strowig, T., Kau, A.L., et al. NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell 145 (2011), 745–757.
40. 40 Dheer, R., Santaolalla, R., Davies, J.M., et al. Intestinal epithelial Toll-like receptor 4 signaling affects epithelial function and colonic microbiota and promotes a risk for transmissible colitis. Infect Immun 84 (2016), 798–810.
41. 41 Gevers, D., Kugathasan, S., Denson, L.A., et al. The treatment-naive microbiome in new-onset Crohn's disease. Cell Host Microbe 15 (2014), 382–392.
42. 42 Gruber, L., Kisling, S., Lichti, P., et al. High fat diet accelerates pathogenesis of murine Crohn's disease-like ileitis independently of obesity. PLoS One, 8, 2013, e71661.
43. 43 Paik, J., Fierce, Y., Treuting, P.M., et al. High-fat diet-induced obesity exacerbates inflammatory bowel disease in genetically susceptible Mdr1a-/- male mice. J Nutr 143 (2013), 1240–1247.
44. 44 van der Logt, E.M., Blokzijl, T., van der Meer, R., et al. Westernized high-fat diet accelerates weight loss in dextran sulfate sodium-induced colitis in mice, which is further aggravated by supplementation of heme. J Nutr Biochem 24 (2013), 1159–1165.
45. 45 Ma, X., Torbenson, M., Hamad, A.R., et al. High-fat diet modulates non-CD1d-restricted natural killer T cells and regulatory T cells in mouse colon and exacerbates experimental colitis. Clin Exp Immunol 151 (2008), 130–138.
46. 46 Davies, J.M., Hua, H.U., Dheer, R., et al. Stool phospholipid signature is altered by diet and tumors. PLoS One, 9, 2014, e114352.
47. 47 Devkota, S., Wang, Y., Musch, M.W., et al. Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in Il10-/- mice. Nature 487 (2012), 104–108.
48. 48 Kevans, D., Turpin, W., Madsen, K., et al. Determinants of intestinal permeability in healthy first-degree relatives of individuals with Crohn's disease. Inflamm Bowel Dis 21 (2015), 879–887.
49. 49 Kevans, D., Silverberg, M.S., Borowski, K., et al. IBD genetic risk profile in healthy first-degree relatives of Crohn's disease patients. J Crohns Colitis 10 (2016), 209–215.
50. 50 Williams Turpin, O.K., Shestopaloff, K., Espin-Garcia, O., et al. 86 Associations of environmental exposures with the composition and diversity of the human gut microbiome in healthy first degree relatives (FDR) of Crohn's patients. Gastroenterology 150 (2016), S21–S22.
51. 51 Limdi, J.K., Aggarwal, D., McLaughlin, J.T., Dietary practices and beliefs in patients with inflammatory bowel disease. Inflamm Bowel Dis 22 (2016), 164–170.
52. 52 Zallot, C., Quilliot, D., Chevaux, J.B., et al. Dietary beliefs and behavior among inflammatory bowel disease patients. Inflamm Bowel Dis 19 (2013), 66–72.
53. 53 Tanaka, M., Kawakami, A., Iwao, Y., et al. Coping strategies for possible flare-ups and their perceived effectiveness in patients with inflammatory bowel disease. Gastroenterol Nurs 39 (2016), 42–47.
54. 54 Jowett, S.L., Seal, C.J., Pearce, M.S., et al. Influence of dietary factors on the clinical course of ulcerative colitis: a prospective cohort study. Gut 53 (2004), 1479–1484.
55. 55 Magee, E.A., Edmond, L.M., Tasker, S.M., et al. Associations between diet and disease activity in ulcerative colitis patients using a novel method of data analysis. Nutr J, 4, 2005, 7.
56. 56 Tanaka, M., Iwao, Y., Sasaki, S., et al. Moderate dietary temperance effectively prevents relapse of Crohn disease: a prospective study of patients in remission. Gastroenterol Nurs 30 (2007), 202–210.
57. 57 Guerreiro, C.S., Ferreira, P., Tavares, L., et al. Fatty acids, IL6, and TNFalpha polymorphisms: an example of nutrigenetics in Crohn's disease. Am J Gastroenterol 104 (2009), 2241–2249.
58. 58 Ferreira, P., Cravo, M., Guerreiro, C.S., et al. Fat intake interacts with polymorphisms of caspase9, Fas ligand and PPARgamma apoptotic genes in modulating Crohn's disease activity. Clin Nutr 29 (2010), 819–823.
59. 59 Reifen, R., Matas, Z., Zeidel, L., et al. Iron supplementation may aggravate inflammatory status of colitis in a rat model. Dig Dis Sci 45 (2000), 394–397.
60. 60 Carrier, J., Aghdassi, E., Cullen, J., et al. Iron supplementation increases disease activity and vitamin E ameliorates the effect in rats with dextran sulfate sodium-induced colitis. J Nutr 132 (2002), 3146–3150.
61. 61 Reifen, R., Nissenkorn, A., Matas, Z., et al. 5-ASA and lycopene decrease the oxidative stress and inflammation induced by iron in rats with colitis. J Gastroenterol 39 (2004), 514–519.
62. 62 Le Leu, R.K., Young, G.P., Hu, Y., et al. Dietary red meat aggravates dextran sulfate sodium-induced colitis in mice whereas resistant starch attenuates inflammation. Dig Dis Sci 58 (2013), 3475–3482.
63. 63 Schepens, M.A., Vink, C., Schonewille, A.J., et al. Dietary heme adversely affects experimental colitis in rats, despite heat-shock protein induction. Nutrition 27 (2011), 590–597.
64. 64 Yeoh, B.S., Aguilera Olvera, R., Singh, V., et al. Epigallocatechin-3-gallate inhibition of myeloperoxidase and its counter-regulation by dietary iron and lipocalin 2 in murine model of gut inflammation. Am J Pathol 186 (2016), 912–926.
65. 65 Lee, T., Clavel, T., Smirnov, K., et al. Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD. Gut, 2016.
66. 66 Dogan, B., Suzuki, H., Herlekar, D., et al. Inflammation-associated adherent-invasive Escherichia coli are enriched in pathways for use of propanediol and iron and M-cell translocation. Inflamm Bowel Dis 20 (2014), 1919–1932.
67. 67 de Silva, A.D., Tsironi, E., Feakins, R.M., et al. Efficacy and tolerability of oral iron therapy in inflammatory bowel disease: a prospective, comparative trial. Aliment Pharmacol Ther 22 (2005), 1097–1105.
68. 68 Hartman, C., Marderfeld, L., Davidson, K., et al. Food intake adequacy in children and adolescents with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 63 (2016), 437–444.
69. 69 Lochs, H., Dejong, C., Hammarqvist, F., et al. ESPEN guidelines on enteral nutrition: gastroenterology. Clin Nutr 25 (2006), 260–274.
70. 70 Sandhu, B.K., Fell, J.M., Beattie, R.M., et al. Guidelines for the management of inflammatory bowel disease in children in the United Kingdom. J Pediatr Gastroenterol Nutr 50:Suppl 1 (2010), S1–S13.
71. 71 Caprilli, R., Gassull, M.A., Escher, J.C., et al. European evidence based consensus on the diagnosis and management of Crohn's disease: special situations. Gut 55:Suppl 1 (2006), i36–58.
72. 72 Borrelli, O., Cordischi, L., Cirulli, M., et al. Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn's disease: a randomized controlled open-label trial. Clin Gastroenterol Hepatol 4 (2006), 744–753.
73. 73 Grover, Z., Muir, R., Lewindon, P., Exclusive enteral nutrition induces early clinical, mucosal and transmural remission in paediatric Crohn's disease. J Gastroenterol 49 (2014), 638–645.
74. 74 Zachos, M., Tondeur, M., Griffiths, A.M., Enteral nutritional therapy for induction of remission in Crohn's disease. Cochrane Database Syst Rev, 1, 2007, CD000542.
75. 75 Takagi, S., Utsunomiya, K., Kuriyama, S., et al. Effectiveness of an ‘half elemental diet’ as maintenance therapy for Crohn's disease: a randomized-controlled trial. Aliment Pharmacol Ther 24 (2006), 1333–1340.
76. 76 Nguyen, D.L., Palmer, L.B., Nguyen, E.T., et al. Specialized enteral nutrition therapy in Crohn's disease patients on maintenance infliximab therapy: a meta-analysis. Therap Adv Gastroenterol 8 (2015), 168–175.
77. 77 Tsertsvadze, A., Gurung, T., Court, R., et al. Clinical effectiveness and cost-effectiveness of elemental nutrition for the maintenance of remission in Crohn's disease: a systematic review and meta-analysis. Health Technol Assess 19 (2015), 1–138.
78. 78 Alastair, F., Emma, G., Emma, P., Nutrition in inflammatory bowel disease. JPEN J Parenter Enteral Nutr 35 (2011), 571–580.
79. 79 Gonzalez-Huix, F., Fernandez-Banares, F., Esteve-Comas, M., et al. Enteral versus parenteral nutrition as adjunct therapy in acute ulcerative colitis. Am J Gastroenterol 88 (1993), 227–232.
80. 80 Lee, D., Baldassano, R.N., Otley, A.R., et al. Comparative effectiveness of nutritional and biological therapy in North American children with active Crohn's disease. Inflamm Bowel Dis 21 (2015), 1786–1793.
81. 81 Papada, E., Kaliora, A.C., Gioxari, A., et al. Anti-inflammatory effect of elemental diets with different fat composition in experimental colitis. Br J Nutr 111 (2014), 1213–1220.
82. 82 Kono, H., Fujii, H., Ogiku, M., et al. Enteral diets enriched with medium-chain triglycerides and N-3 fatty acids prevent chemically induced experimental colitis in rats. Transl Res 156 (2010), 282–291.
83. 83 Cohen, A.B., Lee, D., Long, M.D., et al. Dietary patterns and self-reported associations of diet with symptoms of inflammatory bowel disease. Dig Dis Sci 58 (2013), 1322–1328.
84. 84 Zallot, C., Quilliot, D., Chevaux, J.B., et al. Dietary beliefs and behavior among inflammatory bowel disease patients. Inflamm Bowel Dis 19 (2013), 66–72.
85. 85 Gottschall, E., Breaking the vicious cycle. 1994, Kirkton Press, Baltimore, ON, Canada.
86. 86 Hou, J.K., Lee, D., Lewis, J., Diet and inflammatory bowel disease: review of patient-targeted recommendations. Clin Gastroenterol Hepatol 12 (2014), 1592–1600.
87. 87 Suskind, D.L., Wahbeh, G., Gregory, N., et al. Nutritional therapy in pediatric Crohn disease: the specific carbohydrate diet. J Pediatr Gastroenterol Nutr 58 (2014), 87–91.
88. 88 Obih, C., Wahbeh, G., Lee, D., et al. Specific carbohydrate diet for pediatric inflammatory bowel disease in clinical practice within an academic IBD center. Nutrition 32 (2016), 418–425.
89. 89 Cohen, S.A., Gold, B.D., Oliva, S., et al. Clinical and mucosal improvement with specific carbohydrate diet in pediatric Crohn disease. Pediatr Gastroenterol Nutr 59 (2014), 516–521.
90. 90 Riordan, A.M., Hunter, J.O., Cowan, R.E., et al. Treatment of active Crohn's disease by exclusion diet: East Anglian multicentre controlled trial. Lancet 342 (1993), 1131–1134.
91. 91 Bartel, G., Weiss, I., Turetschek, K., et al. Ingested matter affects intestinal lesions in Crohn's disease. Inflamm Bowel Dis 14 (2008), 374–382.
92. 92 Jones, V.A., Dickinson, R.J., Workman, E., et al. Crohn's disease: maintenance of remission by diet. Lancet 2 (1985), 177–180.
93. 93 Sigall-Boneh, R., Pfeffer-Gik, T., Segal, I., et al. Partial enteral nutrition with a Crohn's disease exclusion diet is effective for induction of remission in children and young adults with Crohn's disease. Inflamm Bowel Dis 20 (2014), 1353–1360.
94. 94 Rajendran, N., Kumar, D., Food-specific IgG4-guided exclusion diets improve symptoms in Crohn's disease: a pilot study. Colorectal Dis 13 (2011), 1009–1013.
95. 95 Chiba, M., Abe, T., Tsuda, H., et al. Lifestyle-related disease in Crohn's disease: relapse prevention by a semi-vegetarian diet. World J Gastroenterol 16 (2010), 2484–2495.
96. 96 Olendzki, B.C., Silverstein, T.D., Persuitte, G.M., et al. An anti-inflammatory diet as treatment for inflammatory bowel disease: a case series report. Nutr J, 13, 2014, 5.
97. 97 Wagner, S.J., Schmidt, A., Effenberger, M.J., et al. Semisynthetic diet ameliorates Crohn's disease-like ileitis in TNFDeltaARE/WT mice through antigen-independent mechanisms of gluten. Inflamm Bowel Dis 19 (2013), 1285–1294.
98. 98 Nickerson, K.P., McDonald, C., Crohn's disease-associated adherent-invasive Escherichia coli adhesion is enhanced by exposure to the ubiquitous dietary polysaccharide maltodextrin. PLoS One, 7, 2012, e52132.
99. 99 Gunasekeera, V., Mendall, M.A., Chan, D., et al. Treatment of Crohn's disease with an IgG4-guided exclusion diet: a randomized controlled trial. Dig Dis Sci 61 (2016), 1148–1157.
100. 100 Truelove, S.C., Ulcerative colitis provoked by milk. Br Med J 1 (1961), 154–160.
101. 101 Florin, T., Neale, G., Gibson, G.R., et al. Metabolism of dietary sulphate: absorption and excretion in humans. Gut 32 (1991), 766–773.
102. 102 Levine, J., Ellis, C.J., Furne, J.K., et al. Fecal hydrogen sulfide production in ulcerative colitis. Am J Gastroenterol 93 (1998), 83–87.
103. 103 Magee, E.A., Richardson, C.J., Hughes, R., et al. Contribution of dietary protein to sulfide production in the large intestine: an in vitro and a controlled feeding study in humans. Am J Clin Nutr 72 (2000), 1488–1494.
104. 104 Laue, H., Denger, K., Cook, A.M., Taurine reduction in anaerobic respiration of Bilophila wadsworthia RZATAU. Appl Environ Microbiol 63 (1997), 2016–2021.
105. 105 Laue, H., Cook, A.M., Biochemical and molecular characterization of taurine:pyruvate aminotransferase from the anaerobe Bilophila wadsworthia. Eur J Biochem 267 (2000), 6841–6848.
106. 106 Medani, M., Collins, D., Docherty, N.G., et al. Emerging role of hydrogen sulfide in colonic physiology and pathophysiology. Inflamm Bowel Dis 17 (2011), 1620–1625.
107. 107 Attene-Ramos, M.S., Nava, G.M., Muellner, M.G., et al. DNA damage and toxicogenomic analyses of hydrogen sulfide in human intestinal epithelial FHs 74 Int cells. Environ Mol Mutagen 51 (2010), 304–314.
108. 108 Attene-Ramos, M.S., Wagner, E.D., Gaskins, H.R., et al. Hydrogen sulfide induces direct radical-associated DNA damage. Mol Cancer Res 5 (2007), 455–459.
109. 109 Attene-Ramos, M.S., Wagner, E.D., Plewa, M.J., et al. Evidence that hydrogen sulfide is a genotoxic agent. Mol Cancer Res 4 (2006), 9–14.
110. 110 Roediger, W.E., Duncan, A., Kapaniris, O., et al. Reducing sulfur compounds of the colon impair colonocyte nutrition: implications for ulcerative colitis. Gastroenterology 104 (1993), 802–809.
111. 111 Babidge, W., Millard, S., Roediger, W., Sulfides impair short chain fatty acid beta-oxidation at acyl-CoA dehydrogenase level in colonocytes: implications for ulcerative colitis. Mol Cell Biochem 181 (1998), 117–124.
112. 112 Rey, F.E., Gonzalez, M.D., Cheng, J., et al. Metabolic niche of a prominent sulfate-reducing human gut bacterium. Proc Natl Acad Sci U S A 110 (2013), 13582–13587.
113. 113 Gibson, G.R., Cummings, J.H., Macfarlane, G.T., Growth and activities of sulphate-reducing bacteria in gut contents of healthy subjects and patients with ulcerative colitis. FEMS Microbiol Lett 86 (1991), 103–112.
114. 114 Pitcher, M.C., Beatty, E.R., Cummings, J.H., The contribution of sulphate reducing bacteria and 5-aminosalicylic acid to faecal sulphide in patients with ulcerative colitis. Gut 46 (2000), 64–72.
115. 115 Fite, A., Macfarlane, G.T., Cummings, J.H., et al. Identification and quantitation of mucosal and faecal desulfovibrios using real time polymerase chain reaction. Gut 53 (2004), 523–529.
116. 116 Loubinoux, J., Bronowicki, J.P., Pereira, I.A., et al. Sulfate-reducing bacteria in human feces and their association with inflammatory bowel diseases. FEMS Microbiol Ecol 40 (2002), 107–112.
117. 117 Edmond, L.M., Hopkins, M.J., Magee, E.A., et al. The effect of 5-aminosalicylic acid-containing drugs on sulfide production by sulfate-reducing and amino acid-fermenting bacteria. Inflamm Bowel Dis 9 (2003), 10–17.
118. 118 Moore, J., Babidge, W., Millard, S., et al. Colonic luminal hydrogen sulfide is not elevated in ulcerative colitis. Dig Dis Sci 43 (1998), 162–165.
119. 119 Hou, J.K., Lee, D., Lewis, J., Diet and inflammatory bowel disease: review of patient-targeted recommendations. Clin Gastroenterol Hepatol 12 (2014), 1592–1600.
120. 120 Gearry, R.B., Irving, P.M., Barrett, J.S., et al. Reduction of dietary poorly absorbed short-chain carbohydrates (FODMAPs) improves abdominal symptoms in patients with inflammatory bowel disease-a pilot study. J Crohns Colitis 3 (2009), 8–14.
121. 121 Prince, A.C., Myers, C.E., Joyce, T., et al. Fermentable carbohydrate restriction (low FODMAP diet) in clinical practice improves functional gastrointestinal symptoms in patients with inflammatory bowel disease. Inflamm Bowel Dis 22 (2016), 1129–1136.
122. 122 Gibson, P.R., Varney, J., Malakar, S., et al. Food components and irritable bowel syndrome. Gastroenterology 148 (2015), 1158–1174.e4.
123. 123 Halmos, E.P., Christophersen, C.T., Bird, A.R., et al. Diets that differ in their FODMAP content alter the colonic luminal microenvironment. Gut 64 (2015), 93–100.
124. 124 Halmos, E.P., Christophersen, C.T., Bird, A.R., et al. Consistent prebiotic effect on gut microbiota with altered FODMAP intake in patients with Crohn's disease: a randomised, controlled cross-over trial of well-defined diets. Clin Transl Gastroenterol, 7, 2016, e164.
125. 125 Wong, C., Harris, P.J., Ferguson, L.R., Potential benefits of dietary fibre intervention in inflammatory bowel disease. Int J Mol Sci, 17, 2016, 6.
126. 126 Slavin, J.L., Position of the American Dietetic Association: health implications of dietary fiber. J Am Diet Assoc 108 (2008), 1716–1731.
127. 127 Crohn's and Colitis Foundation of America. Diet, nutrition, and inflammatory bowel disease. 2013. http://www.ccfa.org/assets/pdfs/diet-nutrition-2013.pdf. Accessed December 22, 2016.
128. 128 World Gastroenterology Organisation. World Gastroenterology Organisation global guidelines inflammatory bowel disease. 2015. http://www.worldgastroenterology.org/UserFiles/file/guidelines/inflammatory-bowel-disease-english-2015-update.pdf. Accessed December 22, 2016.
129. 129 Brotherton, C.S., Martin, C.A., Long, M.D., et al. Avoidance of fiber is associated with greater risk of Crohn's disease flare in a 6-month period. Clin Gastroenterol Hepatol 14 (2016), 1130–1136.
130. 130 Wedlake, L., Slack, N., Andreyev, H.J., et al. Fiber in the treatment and maintenance of inflammatory bowel disease: a systematic review of randomized controlled trials. Inflamm Bowel Dis 20 (2014), 576–586.
131. 131 Benjamin, J.L., Hedin, C.R., Koutsoumpas, A., et al. Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn's disease. Gut 60 (2011), 923–929.
132. 132 Vinolo, M.A., Rodrigues, H.G., Nachbar, R.T., et al. Regulation of inflammation by short chain fatty acids. Nutrients 3 (2011), 858–876.
133. 133 Kim, S., Kim, J.H., Park, B.O., et al. Perspectives on the therapeutic potential of short-chain fatty acid receptors. BMB Rep 47 (2014), 173–178.
134. 134 Huda-Faujan, N., Abdulamir, A.S., Fatimah, A.B., et al. The impact of the level of the intestinal short chain fatty acids in inflammatory bowel disease patients versus healthy subjects. Open Biochem J 4 (2010), 53–58.
135. 135 Hague, A., Singh, B., Paraskeva, C., Butyrate acts as a survival factor for colonic epithelial cells: further fuel for the in vivo versus in vitro debate. Gastroenterology 112 (1997), 1036–1040.
136. 136 Ritzhaupt, A., Ellis, A., Hosie, K.B., et al. The characterization of butyrate transport across pig and human colonic luminal membrane. J Physiol 507 (1998), 819–830.
137. 137 Macfarlane, S., Macfarlane, G.T., Regulation of short-chain fatty acid production. Proc Nutr Soc 62 (2003), 67–72.
138. 138 Barcenilla, A., Pryde, S.E., Martin, J.C., et al. Phylogenetic relationships of butyrate-producing bacteria from the human gut. Appl Environ Microbiol 66 (2000), 1654–1661.
139. 139 Pituch-Zdanowska, A., Banaszkiewicz, A., Albrecht, P., The role of dietary fibre in inflammatory bowel disease. Prz Gastroenterol 10 (2015), 135–141.
140. 140 Schwiertz, A., Le Blay, G., Blaut, M., Quantification of different Eubacterium spp. in human fecal samples with species-specific 16S rRNA-targeted oligonucleotide probes. Appl Environ Microbiol 66 (2000), 375–382.
141. 141 Hold, G.L., Schwiertz, A., Aminov, R.I., et al. Oligonucleotide probes that detect quantitatively significant groups of butyrate-producing bacteria in human feces. Appl Environ Microbiol 69 (2003), 4320–4324.
142. 142 Aminov, R.I., Walker, A.W., Duncan, S.H., et al. Molecular diversity, cultivation, and improved detection by fluorescent in situ hybridization of a dominant group of human gut bacteria related to Roseburia spp. or Eubacterium rectale. Appl Environ Microbiol 72 (2006), 6371–6376.
143. 143 Louis, P., Hold, G.L., Flint, H.J., The gut microbiota, bacterial metabolites and colorectal cancer. Nat Rev Microbiol 12 (2014), 661–672.
144. 144 Wu, G.D., Compher, C., Chen, E.Z., et al. Comparative metabolomics in vegans and omnivores reveal constraints on diet-dependent gut microbiota metabolite production. Gut 65 (2016), 63–72.
145. 145 Brown, A.J., Goldsworthy, S.M., Barnes, A.A., et al. The orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J Biol Chem 278 (2003), 11312–11319.
146. 146 Le Poul, E., Loison, C., Struyf, S., et al. Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. J Biol Chem 278 (2003), 25481–25489.
147. 147 Ganapathy, V., Thangaraju, M., Prasad, P.D., et al. Transporters and receptors for short-chain fatty acids as the molecular link between colonic bacteria and the host. Curr Opin Pharmacol 13 (2013), 869–874.
148. 148 Maslowski, K.M., Vieira, A.T., Ng, A., et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature 461 (2009), 1282–1286.
149. 149 Suzuki, T., Yoshida, S., Hara, H., Physiological concentrations of short-chain fatty acids immediately suppress colonic epithelial permeability. Br J Nutr 100 (2008), 297–305.
150. 150 Macia, L., Tan, J., Vieira, A.T., et al. Metabolite-sensing receptors GPR43 and GPR109A facilitate dietary fibre-induced gut homeostasis through regulation of the inflammasome. Nat Commun, 6, 2015, 6734.
151. 151 Koleva, P.T., Valcheva, R.S., Sun, X., et al. Inulin and fructo-oligosaccharides have divergent effects on colitis and commensal microbiota in HLA-B27 transgenic rats. Br J Nutr 108 (2012), 1633–1643.
152. 152 Bassaganya-Riera, J., DiGuardo, M., Viladomiu, M., et al. Soluble fibers and resistant starch ameliorate disease activity in interleukin-10-deficient mice with inflammatory bowel disease. J Nutr 141 (2011), 1318–1325.
153. 153 Capitan-Canadas, F., Ocon, B., Aranda, C.J., et al. Fructooligosaccharides exert intestinal anti-inflammatory activity in the CD4+ CD62L+ T cell transfer model of colitis in C57BL/6J mice. Eur J Nutr 55 (2016), 1445–1454.
154. 154 Scarminio, V., Fruet, A.C., Witaicenis, A., et al. Dietary intervention with green dwarf banana flour (Musa sp AAA) prevents intestinal inflammation in a trinitrobenzenesulfonic acid model of rat colitis. Nutr Res 32 (2012), 202–209.
155. 155 Videla, S., Vilaseca, J., Antolin, M., et al. Dietary inulin improves distal colitis induced by dextran sodium sulfate in the rat. Am J Gastroenterol 96 (2001), 1486–1493.
156. 156 Rumi, G., Tsubouchi, R., Okayama, M., et al. Protective effect of lactulose on dextran sulfate sodium-induced colonic inflammation in rats. Dig Dis Sci 49 (2004), 1466–1472.
157. 157 Hoentjen, F., Welling, G.W., Harmsen, H.J., et al. Reduction of colitis by prebiotics in HLA-B27 transgenic rats is associated with microflora changes and immunomodulation. Inflamm Bowel Dis 11 (2005), 977–985.
158. 158 Joo, E., Yamane, S., Hamasaki, A., et al. Enteral supplement enriched with glutamine, fiber, and oligosaccharide attenuates experimental colitis in mice. Nutrition 29 (2013), 549–555.
159. 159 Koleva, P., Ketabi, A., Valcheva, R., et al. Chemically defined diet alters the protective properties of fructo-oligosaccharides and isomalto-oligosaccharides in HLA-B27 transgenic rats. PLoS One, 9, 2014, e111717.
160. 160 Scheppach, W., Sommer, H., Kirchner, T., et al. Effect of butyrate enemas on the colonic mucosa in distal ulcerative colitis. Gastroenterology 103 (1992), 51–56.
161. 161 Vernia, P., Marcheggiano, A., Caprilli, R., et al. Short-chain fatty acid topical treatment in distal ulcerative colitis. Aliment Pharmacol Ther 9 (1995), 309–313.
162. 162 Steinhart, A.H., Hiruki, T., Brzezinski, A., et al. Treatment of left-sided ulcerative colitis with butyrate enemas: a controlled trial. Aliment Pharmacol Ther 10 (1996), 729–736.
163. 163 Calder, P.C., Polyunsaturated fatty acids and inflammation. Biochem Soc Trans 33 (2005), 423–427.
164. 164 Feagan, B.G., Sandborn, W.J., Mittmann, U., et al. Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC Randomized Controlled Trials. JAMA 299 (2008), 1690–1697.
165. 165 de Silva, P.S., Olsen, A., Christensen, J., et al. An association between dietary arachidonic acid, measured in adipose tissue, and ulcerative colitis. Gastroenterology 139 (2010), 1912–1917.
166. 166 Matsunaga, H., Hokari, R., Kurihara, C., et al. Omega-3 polyunsaturated fatty acids ameliorate the severity of ileitis in the senescence accelerated mice (SAM)P1/Yit mice model. Clin Exp Immunol 158 (2009), 325–333.
167. 167 Tyagi, A., Kumar, U., Reddy, S., et al. Attenuation of colonic inflammation by partial replacement of dietary linoleic acid with alpha-linolenic acid in a rat model of inflammatory bowel disease. Br J Nutr 108 (2012), 1612–1622.
168. 168 Tyagi, A., Kumar, U., Santosh, V.S., et al. Partial replacement of dietary linoleic acid with long chain n-3 polyunsaturated fatty acids protects against dextran sulfate sodium-induced colitis in rats. Prostaglandins Leukot Essent Fatty Acids 91 (2014), 289–297.
169. 169 Borniquel, S., Jadert, C., Lundberg, J.O., Dietary conjugated linoleic acid activates PPARgamma and the intestinal trefoil factor in SW480 cells and mice with dextran sulfate sodium-induced colitis. J Nutr 142 (2012), 2135–2140.
170. 170 Ibrahim, A., Aziz, M., Hassan, A., et al. Dietary alpha-linolenic acid-rich formula reduces adhesion molecules in rats with experimental colitis. Nutrition 28 (2012), 799–802.
171. 171 Mbodji, K., Charpentier, C., Guerin, C., et al. Adjunct therapy of n-3 fatty acids to 5-ASA ameliorates inflammatory score and decreases NF-kappaB in rats with TNBS-induced colitis. J Nutr Biochem 24 (2013), 700–705.
172. 172 Ferrucci, L., Cherubini, A., Bandinelli, S., et al. Relationship of plasma polyunsaturated fatty acids to circulating inflammatory markers. J Clin Endocrinol Metab 91 (2006), 439–446.
173. 173 Ghosh, S., DeCoffe, D., Brown, K., et al. Fish oil attenuates omega-6 polyunsaturated fatty acid-induced dysbiosis and infectious colitis but impairs LPS dephosphorylation activity causing sepsis. PLoS One, 8, 2013, e55468.
174. 174 Reifen, R., Karlinsky, A., Stark, A.H., et al. alpha-Linolenic acid (ALA) is an anti-inflammatory agent in inflammatory bowel disease. J Nutr Biochem 26 (2015), 1632–1640.
175. 175 Takashima, T., Sakata, Y., Iwakiri, R., et al. Feeding with olive oil attenuates inflammation in dextran sulfate sodium-induced colitis in rat. J Nutr Biochem 25 (2014), 186–192.
176. 176 Sanchez-Fidalgo, S., Cardeno, A., Sanchez-Hidalgo, M., et al. Dietary extra virgin olive oil polyphenols supplementation modulates DSS-induced chronic colitis in mice. J Nutr Biochem 24 (2013), 1401–1413.
177. 177 Mouli, V.P., Ananthakrishnan, A.N., Review article: vitamin D and inflammatory bowel diseases. Aliment Pharmacol Ther 39 (2014), 125–136.
178. 178 Nerich, V., Jantchou, P., Boutron-Ruault, M.C., et al. Low exposure to sunlight is a risk factor for Crohn's disease. Aliment Pharmacol Ther 33 (2011), 940–945.
179. 179 Ananthakrishnan, A.N., Khalili, H., Higuchi, L.M., et al. Higher predicted vitamin D status is associated with reduced risk of Crohn's disease. Gastroenterology 142 (2012), 482–489.
180. 180 Jorgensen, S.P., Agnholt, J., Glerup, H., et al. Clinical trial: vitamin D3 treatment in Crohn's disease - a randomized double-blind placebo-controlled study. Aliment Pharmacol Ther 32 (2010), 377–383.
181. 181 Cantorna, M.T., Munsick, C., Bemiss, C., et al. 1,25-Dihydroxycholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease. J Nutr 130 (2000), 2648–2652.
182. 182 Daniel, C., Radeke, H.H., Sartory, N.A., et al. The new low calcemic vitamin D analog 22-ene-25-oxa-vitamin D prominently ameliorates T helper cell type 1-mediated colitis in mice. J Pharmacol Exp Ther 319 (2006), 622–631.
183. 183 Garg, M., Rosella, O., Lubel, J.S., et al. Association of circulating vitamin D concentrations with intestinal but not systemic inflammation in inflammatory bowel disease. Inflamm Bowel Dis 19 (2013), 2634–2643.
184. 184 Liu, W., Chen, Y., Golan, M.A., et al. Intestinal epithelial vitamin D receptor signaling inhibits experimental colitis. J Clin Invest 123 (2013), 3983–3996.
185. 185 Ooi, J.H., Li, Y., Rogers, C.J., et al. Vitamin D regulates the gut microbiome and protects mice from dextran sodium sulfate-induced colitis. J Nutr 143 (2013), 1679–1686.
186. 186 Assa, A., Vong, L., Pinnell, L.J., et al. Vitamin D deficiency predisposes to adherent-invasive Escherichia coli-induced barrier dysfunction and experimental colonic injury. Inflamm Bowel Dis 21 (2015), 297–306.
187. 187 Golan, M.A., Liu, W., Shi, Y., et al. Transgenic expression of vitamin D receptor in gut epithelial cells ameliorates spontaneous colitis caused by interleukin-10 deficiency. Dig Dis Sci 60 (2015), 1941–1947.
188. 188 Jin, D., Wu, S., Zhang, Y.G., et al. Lack of vitamin D receptor causes dysbiosis and changes the functions of the murine intestinal microbiome. Clin Ther 37 (2015), 996–1009 e7.
189. 189 Li, Y.C., Chen, Y., Du, J., Critical roles of intestinal epithelial vitamin D receptor signaling in controlling gut mucosal inflammation. J Steroid Biochem Mol Biol 148 (2015), 179–183.
190. 190 Ryz, N.R., Lochner, A., Bhullar, K., et al. Dietary vitamin D3 deficiency alters intestinal mucosal defense and increases susceptibility to Citrobacter rodentium-induced colitis. Am J Physiol Gastrointest Liver Physiol 309 (2015), G730–G742.
191. 191 Wu, S., Yoon, S., Zhang, Y.G., et al. Vitamin D receptor pathway is required for probiotic protection in colitis. Am J Physiol Gastrointest Liver Physiol 309 (2015), G341–G349.
192. 192 Wu, S., Zhang, Y.G., Lu, R., et al. Intestinal epithelial vitamin D receptor deletion leads to defective autophagy in colitis. Gut 64 (2015), 1082–1094.
193. 193 Sun, J., VDR/vitamin D receptor regulates autophagic activity through ATG16L1. Autophagy 12 (2016), 1057–1058.
194. 194 Olsen, K.S., Aksnes, L., Froyland, L., et al. Vitamin D status and PUFA ratios in a national representative cross-section of healthy, middle-aged Norwegian women-the Norwegian Women and Cancer Post-Genome Cohort. Scand J Public Health 42 (2014), 814–820.
195. 195 Meckel, K., Li, Y.C., Lim, J., et al. Serum 25-hydroxyvitamin D concentration is inversely associated with mucosal inflammation in patients with ulcerative colitis. Am J Clin Nutr 104 (2016), 113–120.
196. 196 Du, J., Chen, Y., Shi, Y., et al. 1,25-Dihydroxyvitamin D protects intestinal epithelial barrier by regulating the myosin light chain kinase signaling pathway. Inflamm Bowel Dis 21 (2015), 2495–2506.
197. 197 Simpson, H.L., Campbell, B.J., Rhodes, J.M., IBD: microbiota manipulation through diet and modified bacteria. Dig Dis 32:Suppl 1 (2014), 18–25.
198. 198 Chen, Y., Du, J., Zhang, Z., et al. MicroRNA-346 mediates tumor necrosis factor alpha-induced downregulation of gut epithelial vitamin D receptor in inflammatory bowel diseases. Inflamm Bowel Dis 20 (2014), 1910–1918.
199. 199 Zhao, H., Zhang, H., Wu, H., et al. Protective role of 1,25(OH)2 vitamin D3 in the mucosal injury and epithelial barrier disruption in DSS-induced acute colitis in mice. BMC Gastroenterol, 12, 2012, 57.
200. 200 Kong, J., Zhang, Z., Musch, M.W., et al. Novel role of the vitamin D receptor in maintaining the integrity of the intestinal mucosal barrier. Am J Physiol Gastrointest Liver Physiol 294 (2008), G208–G216.
201. 201 Binion, D.G., Otterson, M.F., Rafiee, P., Curcumin inhibits VEGF-mediated angiogenesis in human intestinal microvascular endothelial cells through COX-2 and MAPK inhibition. Gut 57 (2008), 1509–1517.
202. 202 Billerey-Larmonier, C., Uno, J.K., Larmonier, N., et al. Protective effects of dietary curcumin in mouse model of chemically induced colitis are strain dependent. Inflamm Bowel Dis 14 (2008), 780–793.
203. 203 Ukil, A., Maity, S., Karmakar, S., et al. Curcumin, the major component of food flavour turmeric, reduces mucosal injury in trinitrobenzene sulphonic acid-induced colitis. Br J Pharmacol 139 (2003), 209–218.
204. 204 Salh, B., Assi, K., Templeman, V., et al. Curcumin attenuates DNB-induced murine colitis. Am J Physiol Gastrointest Liver Physiol 285 (2003), G235–G243.
205. 205 Sugimoto, K., Hanai, H., Tozawa, K., et al. Curcumin prevents and ameliorates trinitrobenzene sulfonic acid-induced colitis in mice. Gastroenterology 123 (2002), 1912–1922.
206. 206 Binion, D.G., Heidemann, J., Li, M.S., et al. Vascular cell adhesion molecule-1 expression in human intestinal microvascular endothelial cells is regulated by PI 3-kinase/Akt/MAPK/NF-kappaB: inhibitory role of curcumin. Am J Physiol Gastrointest Liver Physiol 297 (2009), G259–G268.
207. 207 Epstein, J., Docena, G., MacDonald, T.T., et al. Curcumin suppresses p38 mitogen-activated protein kinase activation, reduces IL-1beta and matrix metalloproteinase-3 and enhances IL-10 in the mucosa of children and adults with inflammatory bowel disease. Br J Nutr 103 (2010), 824–832.
208. 208 Topcu-Tarladacalisir, Y., Akpolat, M., Uz, Y.H., et al. Effects of curcumin on apoptosis and oxidoinflammatory regulation in a rat model of acetic acid-induced colitis: the roles of c-Jun N-terminal kinase and p38 mitogen-activated protein kinase. J Med Food 16 (2013), 296–305.
209. 209 Aggarwal, B.B., Gupta, S.C., Sung, B., Curcumin: an orally bioavailable blocker of TNF and other pro-inflammatory biomarkers. Br J Pharmacol 169 (2013), 1672–1692.
210. 210 Midura-Kiela, M.T., Radhakrishnan, V.M., Larmonier, C.B., et al. Curcumin inhibits interferon-gamma signaling in colonic epithelial cells. Am J Physiol Gastrointest Liver Physiol 302 (2012), G85–G96.
211. 211 Bereswill, S., Munoz, M., Fischer, A., et al. Anti-inflammatory effects of resveratrol, curcumin and simvastatin in acute small intestinal inflammation. PLoS One, 5, 2010, e15099.
212. 212 Nones, K., Dommels, Y.E., Martell, S., et al. The effects of dietary curcumin and rutin on colonic inflammation and gene expression in multidrug resistance gene-deficient (mdr1a-/-) mice, a model of inflammatory bowel diseases. Br J Nutr 101 (2009), 169–181.
213. 213 McFadden, R.M., Larmonier, C.B., Shehab, K.W., et al. The role of curcumin in modulating colonic microbiota during colitis and colon cancer prevention. Inflamm Bowel Dis 21 (2015), 2483–2494.
214. 214 Lang, A., Salomon, N., Wu, J.C., et al. Curcumin in combination with mesalamine induces remission in patients with mild-to-moderate ulcerative colitis in a randomized controlled trial. Clin Gastroenterol Hepatol 13 (2015), 1444–1449.e1.
215. 215 Hanai, H., Iida, T., Takeuchi, K., et al. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 4 (2006), 1502–1506.
216. 216 Holt, P.R., Curcumin for inflammatory bowel disease: a caution. Clin Gastroenterol Hepatol, 14, 2016, 168.
217. 217 Chassaing, B., Koren, O., Goodrich, J.K., et al. Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome. Nature 519 (2015), 92–96.
218. 218 Walker, A.W., Duncan, S.H., McWilliam Leitch, E.C., et al. pH and peptide supply can radically alter bacterial populations and short-chain fatty acid ratios within microbial communities from the human colon. Appl Environ Microbiol 71 (2005), 3692–3700.
219. 219 Cummings, J.H., Macfarlane, G.T., The control and consequences of bacterial fermentation in the human colon. J Appl Bacteriol 70 (1991), 443–459.
220. 220 McBain, A.J., Macfarlane, G.T., Investigations of bifidobacterial ecology and oligosaccharide metabolism in a three-stage compound continuous culture system. Scand J Gastroenterol Suppl 222 (1997), 32–40.
221. 221 Louis, P., Flint, H.J., Diversity, metabolism and microbial ecology of butyrate-producing bacteria from the human large intestine. FEMS Microbiol Lett 294 (2009), 1–8.
222. 222 Gibson, P.R., Shepherd, S.J., Evidence-based dietary management of functional gastrointestinal symptoms: the FODMAP approach. J Gastroenterol Hepatol 25 (2010), 252–258.
223. 223 Eaton, S.B., Konner, M., Paleolithic nutrition. A consideration of its nature and current implications. N Engl J Med 312 (1985), 283–289.
224. 224 Parish, C., Low residue vs. low fiber diets in inflammatory bowel disease: evidence to support vs. habit?. Pract Gastroenterol 143 (2015), 50–57.
225. 225 Vannice, G., Rasmussen, H., Position of the academy of nutrition and dietetics: dietary fatty acids for healthy adults. J Acad Nutr Diet 114 (2014), 136–153.
226. 226 Millen, B.E., Abrams, S., Adams-Campbell, L., et al. The 2015 Dietary Guidelines Advisory Committee Scientific Report: development and major conclusions. Adv Nutr 7 (2016), 438–444.